Royal Bank Of Canada In8 Bio, Inc. Transaction History

Royal Bank Of Canada

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$0.85 - $1.68 $142 - $282	168 Added 357.45%	215 $0
Q1 2024 Nov 05, 2024	SELL	$0.95 - $1.69 $159 - $283	-168 Reduced 78.14%	47 $0
Q1 2024 May 15, 2024	SELL	$0.95 - $1.69 $206 - $366	-217 Reduced 82.2%	47 $0
Q4 2023 Feb 14, 2024	BUY	$0.69 - $2.34 $102 - $348	149 Added 129.57%	264 $0
Q3 2023 Nov 14, 2023	SELL	$0.92 - $1.74 $136 - $257	-148 Reduced 56.27%	115 $0
Q2 2023 Aug 14, 2023	BUY	$1.05 - $3.24 $227 - $703	217 Added 471.74%	263 $0
Q1 2023 May 15, 2023	BUY	$1.17 - $2.83 $53 - $130	46 New	46 $0
Q3 2022 Nov 14, 2022	BUY	$1.77 - $2.89 $247 - $404	140 New	140 $0

7.62M

Ticker INAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 24,502,200
Market Cap $6.13M
Description
IN8bio, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidate includes INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of...

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

Stay updated on Royal Bank Of Canada with notifications on news.